Imbruvica 140mg Capsule

The human body shows undesired symptoms after taking Imburuvica 140mg Tablet. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.
Some of the common side effects of Imburuvica Tablet are mentioned below:

• High risk of infection
• Vomiting
• Weakness
• Nausea
• Fatigue
• Fever
• Decreased blood cells (red cells, white cells, and platelets), Diarrhea cough

Imburuvica 140mg Tablet is a prescription-based anticancer drug. It is advised to take this tablet after consulting your healthcare expert. This medicine should be taken at the same time every day for better results.

An inhibitor of Bruton's tyrosine kinase is imbruvica 140mg capsule. Inhibiting BTK signaling delays the onset of the disease, inhibits the cancer cells, and encourages apoptosis, or programmed cell death.

This focused strategy lowers the burden of tumors, enhances overall survival rates, and improves patient outcomes.

When taken orally, imbruvica offers long-term, sustained disease control and is a safer option than normal chemotherapy.

It is advised not to miss any scheduled dosage of Imburuvica 140mg Tablet. In case you miss a dose, consult your doctor immediately.

Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Chen, L.S et al., (2018). A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood, 132(21), 2249–2259 - https://pubmed.ncbi.nlm.nih.gov/30254130/
Davids, M. S., & Brown, J. R. (2024). Ibrutinib: A first-in-class covalent inhibitor of Bruton’s tyrosine kinase. Future Oncology, 10(6), 957–967.  Bioequivalence study of Binap® (ibrutinib 140 mg) vs. Imbruvica®. (2024). Journal of Hematology - https://pubmed.ncbi.nlm.nih.gov/24941982/
Janssen Research & Development, LLC. (2024). Study to assess the bioequivalence of ibrutinib 140 mg tablet to 140 mg IMBRUVICA capsule (NCT02877225). ClinicalTrials.go - https://clinicaltrials.gov/study/NCT02877225
Li, S., Young, K. H., & Medeiros, L. J. (2024). [Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL]. Blood Advances, 8(4), 832–841 - https://pmc.ncbi.nlm.nih.gov/articles/PMC10874751/
Ryan, C. (2025). FDA approves generic ibrutinib tablets for B‑cell malignancies. OncLive - https://www.onclive.com/view/fda-approves-generic-ibrutinib-tablets-for-b-cell-malignancies